AVIRAtea Pharmaceuticals, Inc.

AVIR Stock Price, Valuation & Chart | Atea Pharmaceuticals, Inc.

Compare

$5.700+0.21 (+3.83%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology AVIR intrinsic value AVIR calculated fair value vs price

Overview Financials Dividends Ratios

AVIR Historical price chart

AVIR Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization456.15M

PE Ratio-2.7

EPS-2.11

Trading Volume289.92K

Today's High/Low5.73/5.51

Dividend Yield0.00

52 Week High/Low6.45/2.78

Shares Outstanding80.03M

AVIR Financial Statement

AVIR Analyst ratings

AVIR Analysis & performance metrics

AVIR Company profile

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering…

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral…

AVIR Management team

Name

Position

Wayne Foster CPA

Executive Vice President of Finance & Chief Accounting Officer

Xiao-Jian Zhou Ph.D.

Executive Vice President of Early Stage Development

Andrea J. Corcoran J.D.CFO

Chief Financial Officer, Executive Vice President of Legal & Secretary

Adel Moussa Ph.D.

Executive Vice President of Chemistry

Keith Pietropaolo

Executive Vice President of Clinical Sciences & Project Management

John F. Vavricka

Chief Commercial Officer

Jonae R. Barnes

Senior Vice President of Investor Relations & Corporate Communications

Jean-Pierre Sommadossi Ph.D.CEO

Founder, Chairman, Chief Executive Officer & President

Name

Position

Wayne Foster CPA

Executive Vice President of Finance & Chief Accounting Officer

Xiao-Jian Zhou Ph.D.

Executive Vice President of Early Stage Development

Andrea J. Corcoran J.D.CFO

Chief Financial Officer, Executive Vice President of Legal & Secretary

Adel Moussa Ph.D.

Executive Vice President of Chemistry

Keith Pietropaolo

Executive Vice President of Clinical Sciences & Project Management

John F. Vavricka

Chief Commercial Officer

Jonae R. Barnes

Senior Vice President of Investor Relations & Corporate Communications

Jean-Pierre Sommadossi Ph.D.CEO

Founder, Chairman, Chief Executive Officer & President

Management Team

Wayne Foster CPA

Executive Vice President of Finance & Chief Accounting Officer

Xiao-Jian Zhou Ph.D.

Executive Vice President of Early Stage Development

Andrea J. Corcoran J.D.CFO

Chief Financial Officer, Executive Vice President of Legal & Secretary

Adel Moussa Ph.D.

Executive Vice President of Chemistry

Keith Pietropaolo

Executive Vice President of Clinical Sciences & Project Management

John F. Vavricka

Chief Commercial Officer

Jonae R. Barnes

Senior Vice President of Investor Relations & Corporate Communications

Jean-Pierre Sommadossi Ph.D.CEO

Founder, Chairman, Chief Executive Officer & President

Management

Wayne Foster CPA

Executive Vice President of Finance & Chief Accounting Officer

Xiao-Jian Zhou Ph.D.

Executive Vice President of Early Stage Development

Andrea J. Corcoran J.D.CFO

Chief Financial Officer, Executive Vice President of Legal & Secretary

Adel Moussa Ph.D.

Executive Vice President of Chemistry

Keith Pietropaolo

Executive Vice President of Clinical Sciences & Project Management

John F. Vavricka

Chief Commercial Officer

Jonae R. Barnes

Senior Vice President of Investor Relations & Corporate Communications

Jean-Pierre Sommadossi Ph.D.CEO

Founder, Chairman, Chief Executive Officer & President

Total 8 executives

AVIR Frequently asked questions

What is Atea Pharmaceuticals, Inc. (AVIR) Stock Price?

Current stock price of Atea Pharmaceuticals, Inc. (AVIR) stock is $5.700. The stock price is +3.83% higher in the session. The intraday range can be seen from this page. Volume of Atea Pharmaceuticals, Inc. (AVIR) stock is 289.92K.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Atea Pharmaceuticals, Inc. (AVIR) stock price going up or down today?

The stock price of Atea Pharmaceuticals, Inc. (AVIR) can change with earnings, company news, and overall market sentiment. Atea Pharmaceuticals, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Atea Pharmaceuticals, Inc. stock expensive at its current price?

Whether Atea Pharmaceuticals, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for AVIR on this page is -2.70. EPS on this page is -2.11. Compare those figures with peers and growth expectations before deciding if the current Atea Pharmaceuticals, Inc. price is justified.

How has the stock price of Atea Pharmaceuticals, Inc. (AVIR) performed historically?

Historical performance for Atea Pharmaceuticals, Inc. (AVIR) is shown on the price chart on this page. Review multi-period moves alongside volume to see how AVIR reacted to past earnings and market events.

Should I buy Atea Pharmaceuticals, Inc. (AVIR) stock, at this price?

Buying Atea Pharmaceuticals, Inc. (AVIR) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.